Creating a free account will enable you to subscribe to our daily and weekly email newsletters, as well as customize your reading experience to show only the categories most relevant to you.
Signing up only take a few minutes, so why not give it a try and see what you've been missing out on.
For patients with recurrent major depressive disorder that have undergone acute phase cognitive therapy (CT), continuation phase CT (C-CT) does not appear to have greater preventive effects on relapse compared with patients taking fluoxetine (an antidepressant drug) after treatment is stopped, according to a study by Robin B. Jarrett, Ph.D., of The University of Texas Southwestern Medical Center, Dallas, and colleagues.
A total of 523 adults with recurrent major depressive disorder began acute phase CT, of which 241 adults higher-risk responders were randomized to receive eight months of C-CT (n=86), fluoxetine (n=86), or PBO (pill placebo, n=69), and 181 adults subsequently entered the 24 months of longitudinal, posttreatment follow-up.
According to study results, the C-CT or fluoxetine groups were significantly less likely to relapse than the PBO group across eight months. Relapse/recurrence rates for C-CT and fluoxetine were nearly identical during the eight months of treatment, although C-CT patients were more likely to accept randomization, stayed in treatment longer, and attended more sessions than those in the fluoxetine and PBO groups. Contrary to prediction, relapse/recurrence rates following the discontinuation of C-CT and fluoxetine did not differ.
"CT responders at higher risk of relapse/recurrence due to slow or incomplete remission can be safely and effectively treated with either continuation phase CT or switching modalities to fluoxetine," the authors conclude. "After active therapies were discontinued, the preventive effects of both treatments dissipated, suggesting that some higher-risk patients may benefit from additional continuation/maintenance therapies."
Authors made conflict of interest disclosures. The study was funded by grants from the National Institute of Mental Health and supported by Eli Lilly and Co. Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
JAMA Psychiatry. Published online September 4, 2013. doi:10.1001/jamapsychiatry.2013.1969
Article adapted by Medical News Today from original press release. Click 'references' tab above for source.
Visit our Depression category page for the latest news on this subject.
Please use one of the following formats to cite this article in your essay, paper or report:
Psychiatry, JAMA. "Study examines long-term effects of continuation phase cognitive therapy on relapse rate of higher-risk depressive patients." Medical News Today. MediLexicon, Intl., 4 Sep. 2013. Web.
8 Dec. 2013. <http://www.medicalnewstoday.com/releases/265574>
Psychiatry, J. (2013, September 4). "Study examines long-term effects of continuation phase cognitive therapy on relapse rate of higher-risk depressive patients." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
If you write about specific medications, operations, or procedures please do not name healthcare professionals by name.
For any corrections of factual information, or to contact the our editorial team, please use our feedback form. Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
This page was printed from: http://www.medicalnewstoday.com/releases/265574.php
Visit www.medicalnewstoday.com for medical news and health news headlines posted throughout the day, every day.
© 2004-2013 All rights reserved. MNT (logo) is the registered trade mark of MediLexicon International Limited.